Mirum Pharmaceuticals, Inc. balance sheet MIRM

Annual Quarterly

As of Sep 30, 2026, Mirum Pharmaceuticals, Inc. had total assets of $1.0 billion and total liabilities of $1.1 billion. Total assets were up 30.8% from a year earlier. Stockholders' equity was negative, at -$54.2 million, because liabilities exceed assets. It held $500.5 million in cash and investments against $12.3 million of total debt, net cash of $488.1 million. The current ratio, current assets divided by current liabilities, was 2.07.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
Assets
Cash
243
-13.8%
297
+33.3%
223
-22.3%
286
+922.5%
28
-10.6%
31
-77.9%
142
+1087.0%
12
Short-term investments
130
+39.5%
87
+49.9%
58
0
-100.0%
124
-1.2%
125
+39.5%
90
-14.3%
105
Long-term investments
127
+5032.3%
8
-35.3%
13
—
0
-100.0%
5
0
-100.0%
23
Cash and investments
500
+32.4%
391
+33.7%
293
+2.3%
286
+88.7%
152
-6.1%
162
-30.3%
232
+65.6%
140
Receivables
156
+45.9%
123
+57.5%
78
+15.2%
68
+183.3%
24
+634.4%
3
—
—
Inventory
25
+6.1%
25
+11.1%
22
+0.4%
22
+300.9%
6
+267.8%
2
—
—
Total current assets
587
+10.6%
550
+39.9%
393
+1.4%
388
+103.7%
190
+14.2%
167
-29.5%
236
+98.0%
119
Property and equipment, net
3
+154.7%
2
+63.5%
1
+61.3%
1
-22.8%
1
-6.8%
1
-24.1%
1
-5.8%
1
Total assets
1,027
+30.8%
843
+25.7%
671
+3.7%
647
+83.2%
353
+19.8%
295
+22.3%
241
+64.2%
147
Liabilities and equity
Accounts payable
14
+12.2%
10
-34.2%
15
+97.1%
7
-14.7%
9
-5.2%
9
+190.9%
3
-6.0%
3
Total current liabilities
283
+76.5%
206
+62.6%
127
+45.4%
87
+34.5%
65
+52.0%
43
+130.7%
18
+41.2%
13
Total liabilities
1,081
+119.2%
528
+18.6%
445
+11.9%
398
+88.7%
211
+20.9%
174
+153.7%
69
+320.3%
16
Stockholders' equity
-54
-118.6%
315
+39.5%
226
-9.3%
249
+75.1%
142
+18.2%
120
-30.1%
172
+32.0%
130
Debt
Lease liabilities
12
+31.0%
10
-0.3%
10
+462.5%
2
-21.3%
2
-16.3%
3
-19.9%
3
-10.6%
4
Total debt
12
+31.0%
10
-0.3%
10
+462.5%
2
-21.3%
2
-16.3%
3
-19.9%
3
-10.6%
4
Net cash
488
+32.4%
382
+34.8%
283
-0.5%
285
+90.3%
150
-5.9%
159
-30.5%
229
+67.7%
136
Ratios
Current ratio
2.07x
2.67x
3.10x
4.45x
2.94x
3.91x
12.80x
9.13x
Debt to equity
—
0.03x
0.04x
0.01x
0.02x
0.02x
0.02x
0.03x
Debt to EBITDA
—
4.58x
—
—
—
—
—
—
Return on equity
—
-7.42%
-38.97%
-65.72%
-95.51%
-69.87%
-60.01%
-40.32%
Return on assets
-88.04%
-2.77%
-13.11%
-25.27%
-38.44%
-28.50%
-42.87%
-35.82%
Book value per share
-0.83
6.06
4.67
5.32
3.84
3.93
5.78
5.77
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
MIRM (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Foster City, CA
SEC filer status
Large accelerated filer
SEC CIK
1759425

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.